

SA2619 - Etanercept

Plaque psoriasis - Initial application	8
Plaque psoriasis - Renewal	9
Stills disease - adult-onset (AOSD) - Initial application	2
Ankylosing spondylitis - Initial application	3
Ankylosing spondylitis - Renewal	3
Arthritis - oligoarticular course juvenile idiopathic - Initial application	4
Arthritis - oligoarticular course juvenile idiopathic - Renewal	5
Arthritis - polyarticular course juvenile idiopathic - Initial application	4
Arthritis - polyarticular course juvenile idiopathic - Renewal	4
Arthritis - psoriatic - Initial application	5
Arthritis - psoriatic - Renewal	6
Arthritis - rheumatoid - Initial application	7
Arthritis - rheumatoid - Renewal	7
Pyoderma gangrenosum* - Initial application	6
Undifferentiated spondyloarthritis* - Initial application	10
Undifferentiated spondyloarthritis* - Renewal	10

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
.....	Address:	
.....		
.....		

Etanercept

Initial application — Stills disease - adult-onset (AOSD)

Applications from any relevant practitioner. Approvals valid without further renewal unless notified.

Prerequisites(tick boxes where appropriate)

☐ Patient has had a Special Authority approval for adalimumab or tocilizumab for AOSD

and

☐ Patient has experienced intolerable side effects

or

☐ Patient has received insufficient benefit to meet the renewal criteria from at least a 3-month trial of adalimumab or tocilizumab

or

☐ Patient diagnosed with AOSD according to the Yamaguchi criteria

and

☐ Patient has tried and received insufficient benefit from at least 6 months of corticosteroids at a dose of at least 0.5 mg/kg prednisone-equivalents, NSAIDs and methotrexate, unless contraindicated

and

☐ Patient has persistent symptoms of disabling poorly controlled and active disease

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: Date:

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: customerservice@health.govt.nz

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
.....	Address:	
.....		
.....		

Etanercept - continued

Initial application — ankylosing spondylitis

Applications from any relevant practitioner. Approvals valid for 6 months.

Prerequisites(tick boxes where appropriate)

- ☐ Patient has had a Special Authority approval for adalimumab for ankylosing spondylitis
- and
- ☐ Patient has experienced intolerable side effects
- or
- ☐ Patient has received insufficient benefit to meet the renewal criteria for ankylosing spondylitis

- or
- ☐ Patient has a confirmed diagnosis of ankylosing spondylitis
- and
- ☐ Patient has low back pain and stiffness that is relieved by exercise but not by rest
- and
- ☐ Patient has bilateral sacroiliitis demonstrated by radiologic imaging
- and
- ☐ Disease has not responded adequately to treatment with two or more NSAIDs (unless contraindicated), while patient was undergoing at least 3 months of a regular exercise regimen for ankylosing spondylitis
- and
- ☐ Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following BASMI measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right)
- or
- ☐ Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender
- and
- ☐ BASDAI of at least 6 on a 10-point scale completed after 3-month exercise trial before ceasing any previous pharmacological treatment and not more than 1 month before the application

Renewal — ankylosing spondylitis

Current approval Number (if known):.....

Applications from any relevant practitioner. Approvals valid for 2 years.

Prerequisites(tick boxes where appropriate)

- ☐ BASDAI has improved from pre-treatment baseline either by at least 4 points on a 10-point scale, or by at least 50%
- and
- ☐ Maximum dose 50 mg every 7 days

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: Date:

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: customerservice@health.govt.nz

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
.....	Address:	
.....		
.....		

Etanercept - continued

Initial application — arthritis - polyarticular course juvenile idiopathic

Applications from any relevant practitioner. Approvals valid for 6 months.

Prerequisites(tick boxes where appropriate)

☐ Patient has had a Special Authority approval for adalimumab for polyarticular course juvenile idiopathic arthritis (JIA)

and

☐ Patient has experienced intolerable side effects

or

☐ Patient has received insufficient benefit to meet the renewal criteria for polyarticular course JIA

or

☐ At least 5 active joints and at least 3 joints with pain, tenderness or a limited range of motion, after a 3-month trial of methotrexate at the maximum tolerated dose, unless contraindicated

or

☐ Moderate or high disease activity (cJADAS10 score of at least 2.5) after a 3-month trial of methotrexate at the maximum tolerated dose, unless contraindicated

or

☐ Low disease activity (cJADAS10 score between 1.1 and 2.5) after a 6-month trial of methotrexate

Renewal — arthritis - polyarticular course juvenile idiopathic

Current approval Number (if known):.....

Applications from any relevant practitioner. Approvals valid for 2 years.

Prerequisites(tick boxes where appropriate)

☐ Following initial treatment, at least a 50% decrease in active joint count from baseline

or

☐ On subsequent reapplications, at least a continuing 30% improvement in active joint count from baseline

Initial application — arthritis - oligoarticular course juvenile idiopathic

Applications from any relevant practitioner. Approvals valid for 6 months.

Prerequisites(tick boxes where appropriate)

☐ Patient has had a Special Authority approval for adalimumab for oligoarticular course juvenile idiopathic arthritis (JIA)

and

☐ Patient has experienced intolerable side effects

or

☐ Patient has received insufficient benefit to meet the renewal criteria for oligoarticular course JIA

or

☐ At least 2 active joints with pain, tenderness or a limited range of motion, after a 3-month trial of methotrexate at the maximum tolerated dose, unless contraindicated

or

☐ Moderate or high disease activity (cJADAS10 score greater than 1.5) with poor prognostic features after a 3-month trial of methotrexate at the maximum tolerated dose, unless contraindicated

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: Date:

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: customerservice@health.govt.nz

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
.....	Address:	
.....		
.....		

Etanercept - continued

Renewal — arthritis - oligoarticular course juvenile idiopathic

Current approval Number (if known):.....

Applications from any relevant practitioner. Approvals valid for 2 years.

Prerequisites(tick boxes where appropriate)

- ☐ Following initial treatment, at least a 50% decrease in active joint count from baseline
- or
- ☐ On subsequent reapplications, at least a continuing 30% improvement in active joint count from baseline

Initial application — arthritis - psoriatic

Applications from any relevant practitioner. Approvals valid for 6 months.

Prerequisites(tick boxes where appropriate)

☐ Patient has had a Special Authority approval for adalimumab or secukinumab for psoriatic arthritis

and

☐ Patient has experienced intolerable side effects

or

☐ Patient has received insufficient benefit to meet the renewal criteria for psoriatic arthritis

or

☐ Patient has received insufficient benefit from at least 3 months of methotrexate at maximum tolerated dose unless contraindicated

and

☐ Patient received insufficient benefit from at least 3 months of sulfasalazine or leflunomide at maximum tolerated dose unless contraindicated

and

☐ Patient has persistent symptoms of poorly controlled and active disease in at least 15 joints

or

☐ Patient has persistent symptoms of poorly controlled and active disease in at least 4 joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip

and

☐ Patient has a CRP greater than 15 mg/L measured within one month before the application

or

☐ Patient has an ESR greater than 25 mm per hour measured within one month before the application

or

☐ ESR and CRP not measured as patient is receiving prednisone therapy greater than 5 mg per day received for more than 3 months

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: Date:

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: customerservice@health.govt.nz

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
.....	Address:	
.....		
.....		

Etanercept - *continued*

Renewal — arthritis - psoriatic

Current approval Number (if known):.....

Applications from any relevant practitioner. Approvals valid for 2 years.

Prerequisites(tick boxes where appropriate)

- ☐ Following initial treatment, at least a 50% decrease in active joint count from baseline
or
☐ At least a continuing 30% improvement in active joint count from baseline

and

- ☐ Maximum dose 50 mg every 7 days

Initial application — pyoderma gangrenosum*

Applications from any relevant practitioner. Approvals valid without further renewal unless notified.

Prerequisites(tick boxes where appropriate)

- ☐ Patient has received insufficient benefit from 3 months of conventional therapy including a minimum of 3 pharmaceuticals (e.g. prednisone, ciclosporine, azathioprine, or methotrexate). Where conventional pharmaceuticals are contraindicated, a 3 month trial has occurred of those that are not contraindicated

and

- ☐ Maximum of 8 doses every 4 months

Note: Indications marked with * are unapproved indications.

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: Date:

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: customerservice@health.govt.nz

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
.....	Address:	
.....		
.....		

Etanercept - continued

Initial application — arthritis - rheumatoid

Applications from any relevant practitioner. Approvals valid for 6 months.

Prerequisites(tick boxes where appropriate)

☐ Patient has had a Special Authority approval for adalimumab for rheumatoid arthritis

and

☐ Patient has experienced intolerable side effects

or

☐ Patient has received insufficient benefit to meet the renewal criteria for rheumatoid arthritis

or

☐ Patient has had rheumatoid arthritis (either confirmed by radiologic imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive)

and

☐ Patient has received insufficient benefit from at least 3 months of methotrexate at a maximum tolerated dose (unless contraindicated)

and

☐ Patient has received insufficient benefit from at least 3 months of methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate (at maximum tolerated doses unless contraindicated)

and

☐ Patient has received insufficient benefit from at least 3 months of methotrexate in combination with the maximum tolerated dose of ciclosporin, unless contraindicated

or

☐ Patient has received insufficient benefit from at least 3 months of therapy at the maximum tolerated dose of leflunomide alone or in combination with methotrexate, unless contraindicated

and

☐ Patient has persistent symptoms of poorly controlled and active disease in at least 15 joints

or

☐ Patient has persistent symptoms of poorly controlled and active disease in at least 4 joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip

Renewal — arthritis - rheumatoid

Current approval Number (if known):.....

Applications from any relevant practitioner. Approvals valid for 2 years.

Prerequisites(tick boxes where appropriate)

☐ Following initial treatment, at least a 50% decrease in active joint count from baseline

or

☐ On subsequent reapplications, at least a continuing 30% improvement in active joint count from baseline

and

☐ Maximum dose 50 mg every 7 days

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: Date:

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: customerservice@health.govt.nz

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
.....	Address:	
.....		
.....		

Etanercept - continued

Initial application — Plaque psoriasis

Applications from any relevant practitioner. Approvals valid for 6 months.

Prerequisites(tick boxes where appropriate)

- ☐ Patient has had a Special Authority approval for adalimumab for plaque psoriasis
- and
- ☐ Patient has experienced intolerable side effects
- or
- ☐ Patient has received insufficient benefit to meet the renewal criteria for plaque psoriasis

or

- ☐ Patient has "whole body" plaque psoriasis with a PASI score of greater than 10
- or
- ☐ Patient has plaque psoriasis of the face, or palm of a hand or sole of a foot
- or
- ☐ Patient has localised genital or flexural plaque psoriasis with a DLQI score greater than 10
- and
- ☐ Patient has received insufficient benefit from (see Note), or has experienced intolerable side effects from, at least 3 of the following at maximum tolerated doses (unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin
- and
- ☐ A PASI assessment or DLQI assessment has been completed for the most recent prior treatment course within 1 month of stopping that treatment
- and
- ☐ The most recent PASI or DLQI assessment is within 1 month before the application

Note: "Insufficient benefit" is defined as: for whole body plaque psoriasis, a PASI score of greater than 10, for plaque psoriasis of the face, hand, foot, genital or flexural areas at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and for the face, palm of a hand or sole of a foot the skin area affected is 30% or more of the face, palm of a hand or sole of a foot. As assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: Date:

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: customerservice@health.govt.nz

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
.....	Address:	
.....		
.....		

Etanercept - continued

Renewal — Plaque psoriasis

Current approval Number (if known):.....

Applications from any relevant practitioner. Approvals valid for 2 years.

Prerequisites(tick boxes where appropriate)

☐ Patient had "whole body" plaque psoriasis at the start of treatment

and

☐ Patient has a PASI score which is reduced by 75% or more, or is sustained at this level, compared with the pre-treatment baseline

or

☐ Patient has a DLQI improvement of 5 or more, compared with the pre-treatment baseline

or

☐ Patient had plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment

and

☐ Patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, compared to the pre-treatment baseline

or

☐ Patient has a reduction of 75% or more in the skin area affected, or sustained at this level, compared to the pre-treatment baseline

or

☐ Patient has localised genital or flexural plaque psoriasis at the start of treatment

and

☐ Patient has experienced a reduction of 75% or more in the skin area affected, or sustained at this level, compared to the pre-treatment baseline

or

☐ Patient has a DLQI improvement of 5 or more, compared to the pre-treatment baseline

and

☐ Maximum dose 50 mg every 7 days

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: Date:

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: customerservice@health.govt.nz

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
.....	Address:	
.....		
.....		

Etanercept - continued

Initial application — undifferentiated spondyloarthritis*

Applications from any relevant practitioner. Approvals valid for 6 months.

Prerequisites(tick boxes where appropriate)

- ☐ Patient has undifferentiated peripheral spondyloarthritis with active peripheral joint arthritis in at least 4 joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip
- and
- ☐ Patient has received insufficient benefit from least 3 months of each of methotrexate, sulfasalazine, and leflunomide at maximum tolerated doses, unless contraindicated
- and
- ☐ Patient has a CRP level greater than 15 mg/L measured within one month before the application

or

☐ Patient has an ESR greater than 25 mm per hour measured within one month before the application

or

☐ ESR and CRP not measured as patient is currently receiving prednisone therapy greater than 5 mg per day received for more than 3 months

Note: Indications marked with * are unapproved indications.

Renewal — undifferentiated spondyloarthritis*

Current approval Number (if known):.....

Applications from any relevant practitioner. Approvals valid for 2 years.

Prerequisites(tick boxes where appropriate)

- ☐ Following initial treatment, the patient has experienced at least a 50% decrease in active joint count from baseline

or

☐ Patient has experienced at least a continuing 30% improvement in active joint count from baseline
- and
- ☐ Maximum dose 50 mg every 7 days

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: Date:

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: customerservice@health.govt.nz